Core Viewpoint - The Hong Kong Stock Exchange reported a significant increase in IPO fundraising, with a 579% rise in the first eight months of 2025 compared to the same period last year, indicating a robust market recovery and investor confidence [8][11]. Market Performance - On September 4, the Hang Seng Index fell by 1.12%, with the Hang Seng Technology Index down by 1.85% and the Hang Seng China Enterprises Index down by 1.25%. The total market turnover was 302.33 billion HKD, with southbound funds slightly net buying 706 million HKD [2]. - Among the constituent stocks, 27 rose while 56 fell, with notable declines in stocks like Zhongsheng Holdings (-8.85%) and WuXi AppTec (-7.31%) [3]. IPO and Fundraising Statistics - In the first eight months of 2025, the total IPO fundraising in Hong Kong reached 134.5 billion HKD, a substantial increase from 19.8 billion HKD in the same period last year [8]. - The total fundraising in the Hong Kong securities market was 368.8 billion HKD, up from 87.3 billion HKD year-on-year, marking a 322% increase [8]. Trading Volume and Market Activity - The average daily trading volume in the Hong Kong securities market for the first eight months of 2025 was 2.79 billion HKD, a 192% increase from 955 million HKD in the previous year [8]. - The average daily trading volume for exchange-traded funds was 337 million HKD, up 183% from 119 million HKD year-on-year [10]. Company Performance - Sun Hung Kai Properties reported a total revenue of 72.702 billion HKD for the fiscal year 2024/25, reflecting an 8.8% year-on-year growth, with a pre-tax profit of 22.573 billion HKD, up 4.96% [14]. - The company's rental income decreased by 2% to 24.461 billion HKD, primarily due to a decline in turnover rent [17].

新华社香港9月4日电 香港恒生指数4日跌284.92点，跌幅1.12%，收报25058.51点。全日主板成交 3022.33亿港元。 国企指数跌112.93点，收报8937.09点，跌幅1.25%。恒生科技指数跌104.88点，收报5578.86点，跌 幅1.85%。 蓝筹股方面，腾讯控股跌1%，收报592.5港元；香港交易所跌1.23%，收报432.2港元；中国移动跌 0.35%，收报85.4港元；汇丰控股涨0.45%，收报99.6港元。 石油石化股方面，中国石油化工股份跌1.5%，收报4.13港元；中国石油股份跌1.42%，收报7.63港 元；中国海洋石油跌0.4%，收报19.79港元。 【纠错】 【责任编辑:邱丽芳】 香港本地股方面，长实集团涨0.55%，收报36.62港元；新鸿基地产跌0.76%，收报91.4港元；恒基 地产跌0.99%，收报26.04港元。 中资金融股方面，中国银行涨0.23%，收报4.32港元；建设银行跌0.52%，收报7.59港元；工商银行 跌0.17%，收报5.73港元；中国平安跌1.5%，收报55.65港元；中国人寿跌3.28%，收报22.4港元。 ...

Market Overview - The total market capitalization of the Hong Kong securities market reached HKD 46.6 trillion at the end of August 2025, a 47% increase from HKD 31.8 trillion in the same period last year [1] - The average daily trading amount in August was HKD 279.1 billion, up 192% from HKD 95.5 billion year-on-year [1] - For the first eight months of 2025, the average daily trading amount was HKD 248.3 billion, a 132% increase from HKD 106.8 billion in the same period last year [1] Derivative Products - The average daily trading volume of futures and options for the first eight months of 2025 was 1,660,900 contracts, a 13% increase from 1,473,911 contracts year-on-year [2] - The average daily trading volume of stock options was 863,627 contracts, up 29% from 670,560 contracts last year [2] - The average daily trading volume of RMB currency futures was 112,121 contracts, a 30% increase from 86,010 contracts year-on-year [2] New Listings and Fundraising - There were 59 new listings in the first eight months of 2025, a 37% increase from 43 new listings in the same period last year [1] - The total amount raised through initial public offerings (IPOs) was HKD 134.5 billion, a significant increase of 579% from HKD 19.8 billion year-on-year [1] - The total fundraising amount for the first eight months reached HKD 368.8 billion, up 322% from HKD 87.3 billion last year [1]

Market Overview - The total market capitalization of the Hong Kong securities market reached HKD 46.6 trillion at the end of August 2025, a 47% increase from HKD 31.8 trillion in the same period last year [1] - The average daily trading amount in August was HKD 279.1 billion, up 192% from HKD 95.5 billion year-on-year [1] - For the first eight months of 2025, the average daily trading amount was HKD 248.3 billion, a 132% increase from HKD 106.8 billion in the same period last year [1] Derivative Products - The average daily trading volume of futures and options for the first eight months of 2025 was 1,660,900 contracts, a 13% increase from 1,473,911 contracts year-on-year [2] - The average daily trading volume of stock options was 863,627 contracts, up 29% from 670,560 contracts in the previous year [2] - The average daily trading volume of RMB currency futures was 112,121 contracts, a 30% increase from 86,010 contracts year-on-year [2] New Listings and Fundraising - There were 59 new listed companies in the first eight months of 2025, a 37% increase from 43 companies in the same period last year [1] - The total amount raised through initial public offerings (IPOs) was HKD 134.5 billion, a significant increase of 579% from HKD 19.8 billion year-on-year [1] - The total fundraising amount for the first eight months reached HKD 368.8 billion, up 322% from HKD 87.3 billion in the previous year [1]

港交所披露数据显示，证券市场市价总值于2025年8月底为46.6万亿港元，较去年同期的31.8万亿港元上 升47%。2025年8月的平均每日成交金额为2,791亿港元，较去年同期的955亿港元上升192%。 ...

Core Insights - Long-term institutional investors are revealing their holdings while the market debates short-term volatility [2][18] - Fund managers like Zhang Kun and Ge Lan are making strategic adjustments in their portfolios, indicating their market outlook [2][9] Fund Manager Strategies - Zhang Kun has expressed skepticism about the pessimistic expectations for domestic demand, suggesting that consumer confidence is influenced by income expectations and social security systems [16][17] - Ge Lan is focusing on innovative pharmaceuticals and medical devices, anticipating growth driven by innovation and consumer recovery [17] Portfolio Adjustments - Zhang Kun's fund, E Fund Blue Chip Select, has reduced its stock position slightly, with the top ten holdings now accounting for 83.84% of the fund's net value, the highest in ten quarters [3][4] - The fund has introduced new holdings such as Beike-W and Chao Yan Technology, while previously held stocks like Newell and Mindray Medical have been removed [4][7] Hidden Holdings - The "invisible heavyweights" in Zhang Kun's portfolio include stocks like Focus Media, Meituan-W, and Hong Kong Exchanges, with significant changes in their holdings [4][5] - Ge Lan's hidden holdings also feature stocks like Huadong Medicine and Hualan Biological Engineering, reflecting her focus on the pharmaceutical sector [10][12] Market Performance - The stocks in these funds have generally supported the funds' net value increases, with some stocks experiencing significant price rises since July [14] - The overall market sentiment remains cautious, but long-term investors see opportunities to acquire high-quality stocks at lower valuations [17]

Group 1 - Goldman Sachs reports that Hong Kong Exchanges and Clearing Limited (00388) has simplified trading and settlement fees, and the Securities and Futures Commission has recently expanded the holding limits for derivative products, indicating a step towards simplifying the platform and enhancing capital efficiency for market participants [1] - The firm has raised its earnings per share forecasts for Hong Kong Exchanges for this year, next year, and 2027 by 2%, 3%, and 4% respectively, and increased the target price from HKD 509 to HKD 524, which corresponds to a forecasted price-to-earnings ratio of 40 times for next year [1] - The firm predicts a downward adjustment in the expected yield from Hong Kong's margin balances to 1.97%, 1.39%, and 1.42% for this year, next year, and 2027 respectively, with average daily sales expected to be HKD 249 billion, HKD 275 billion, and HKD 299 billion for the respective years [1]

Group 1 - Goldman Sachs reports that Hong Kong Exchanges and Clearing (00388) has simplified trading and settlement fees, and the Securities and Futures Commission has recently expanded the holding limits for derivative products [1] - The firm views these changes as steps towards simplifying the platform, enhancing capital efficiency for market participants, and aligning with international standards [1] - Earnings per share forecasts for Hong Kong Exchanges and Clearing have been raised by 2%, 3%, and 4% for this year, next year, and 2027 respectively, with the target price increased from HKD 509 to HKD 524, implying a forecasted price-to-earnings ratio of 40 times for next year [1] Group 2 - The firm predicts a decrease in the expected yield from Hong Kong's margin balances to 1.97%, 1.39%, and 1.42% for this year, next year, and 2027 respectively [1] - Daily average sales are projected to be HKD 249 billion, HKD 275 billion, and HKD 299 billion for the respective years [1]

Core Viewpoint - Long-term institutional investors are revealing their positions amidst short-term market fluctuations, indicating a deeper judgment on future market trends by renowned fund managers like Zhang Kun and Ge Lan [2][18]. Group 1: Zhang Kun's Portfolio Adjustments - Zhang Kun's management of the E Fund Blue Chip Select has seen a slight reduction in stock positions, with the stock holding ratio decreasing from 94.14% to 92.63%, marking the lowest level in nearly three years [3]. - The fund's top ten holdings now account for 83.84% of its net value, the highest in the past ten quarters, while the "invisible heavyweights" (ranked 11th to 20th) have significantly decreased from 18.05% to 9.22% [3][4]. - Notable adjustments include a reduction in holdings of Meituan-W by 46.43% and an increase in holdings of Fenzhong Media from 1.53 million shares to 2.48 million shares [4][5]. Group 2: Ge Lan's Focus on Innovative Pharmaceuticals - Ge Lan's management of the China Europe Fund has seen a significant increase in the number of holdings in innovative pharmaceuticals, with the top ten holdings including new entries like Xinli Tai and Bai Li Tian Heng [10][12]. - The fund's turnover rate reached 61.3%, indicating a dynamic adjustment strategy, with a notable increase in the number of innovative drug stocks in the top twenty holdings [10][12]. - Ge Lan emphasizes that the pharmaceutical sector will continue to grow driven by innovation, consumer recovery, and domestic substitution, with a focus on the innovative drug industry chain and consumer healthcare [19][20]. Group 3: Market Sentiment and Future Outlook - Zhang Kun challenges the prevailing pessimistic view on domestic demand, arguing that consumer confidence is influenced by expectations rather than just current economic conditions [18][19]. - Ge Lan anticipates that the pharmaceutical industry will rely on innovation breakthroughs and consumer recovery for growth, despite potential risks from global economic fluctuations [19][20].

Core Viewpoint - Goldman Sachs released a research report indicating that the Hong Kong Stock Exchange (HKEX) is enhancing market efficiency and aligning with international standards by simplifying trading and settlement fees and expanding derivative holding limits [1] Group 1: Revenue and Earnings Forecasts - Based on predictions for Hong Kong interbank offered rates, Goldman Sachs has lowered the revenue yield forecast from margin balances for HKEX for this year, next year, and 2027 [1] - Simultaneously, the company has raised its earnings per share forecast for the same period [1] Group 2: Target Price and Rating - Goldman Sachs has increased the target price for HKEX from 509 HKD to 524 HKD [1] - The firm maintains a "Buy" rating for the stock [1]